The study, which included 110,885 matched pairs, followed participants for an average of 670 days and found a 35% reduction in dementia risk among SGLT2 inhibitor users (HR: 0.65, 95% CI: 0.58–0.73). The gene discussed is SLC5A2; the disease is dementia.